{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:48:02Z","timestamp":1792381682991,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40265-015-0491-x","type":"journal-article","created":{"date-parts":[[2015,12,13]],"date-time":"2015-12-13T03:51:58Z","timestamp":1449978718000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Diagnosis and Management of Systemic Sclerosis: A Practical Approach"],"prefix":"10.1007","volume":"76","author":[{"given":"Jason J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"issue":"3","key":"491_CR1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncprheum0115","volume":"2","author":"CP Denton","year":"2006","unstructured":"Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheum. 2006;2(3):134\u201344.","journal-title":"Nat Clin Pract Rheum."},{"issue":"1","key":"491_CR2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2012","unstructured":"Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012;8(1):42\u201354.","journal-title":"Nat Rev Rheumatol."},{"issue":"19","key":"491_CR3","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989\u20132003.","journal-title":"N Engl J Med."},{"issue":"7","key":"491_CR4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","volume":"10","author":"YY Ho","year":"2014","unstructured":"Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis\u2014a lethal component of systemic sclerosis. Nat Rev Rheumatol. 2014;10(7):390\u2013402.","journal-title":"Nat Rev Rheumatol."},{"issue":"3","key":"491_CR5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.110121","volume":"39","author":"J Pope","year":"2012","unstructured":"Pope J, Harding S, Khimdas S, Bonner A, Baron M, Canadian Scleroderma Research Group. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol. 2012;39(3):524\u201331.","journal-title":"J Rheumatol."},{"key":"491_CR6","doi-asserted-by":"crossref","unstructured":"Walker KM, Pope J, Participating members of the Scleroderma Clinical Trials Consortium, Canadian Scleroderma Research Group. Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2013a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42(1):42\u201355.","DOI":"10.1016\/j.semarthrit.2012.01.003"},{"issue":"7","key":"491_CR7","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.101262","volume":"38","author":"KM Walker","year":"2011","unstructured":"Walker KM, Pope J, Canadian Scleroderma Research Group. Expert agreement on EULAR\/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol. 2011;38(7):1326\u20138.","journal-title":"J Rheumatol."},{"issue":"5","key":"491_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620\u20138.","journal-title":"Ann Rheum Dis."},{"key":"491_CR9","unstructured":"Denton CP, Hughes M, Gak N, Vila J, Buch M, Chakravarty K, et al. BSR and BHPR guideline for the management of systemic sclerosis\u2014executive summary, 2015. In: Presented at the BSR Rheumatology Annual Scientific Congress, Manchester, 2015."},{"issue":"1","key":"491_CR10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0049-0172(82)90023-3","volume":"12","author":"TG Benedek","year":"1982","unstructured":"Benedek TG, Rodnan GP. The early history and nomenclature of scleroderma and of its differentiation from sclerema neonatorum and scleroedema. Semin Arthritis Rheum. 1982;12(1):52\u201367.","journal-title":"Semin Arthritis Rheum."},{"issue":"11","key":"491_CR11","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum."},{"issue":"3","key":"491_CR12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.rdc.2015.04.003","volume":"41","author":"JE Pope","year":"2015","unstructured":"Pope JE, Johnson SR. New classification criteria for systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 2015;41(3):383\u201398.","journal-title":"Rheum Dis Clin North Am."},{"issue":"7","key":"491_CR13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891\u20137.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"6","key":"491_CR14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11926-014-0425-8","volume":"16","author":"R Dobrota","year":"2014","unstructured":"Dobrota R, Mihai C, Distler O. Personalized medicine in systemic sclerosis: facts and promises. Curr Rheumatol Rep. 2014;16(6):425.","journal-title":"Curr Rheumatol Rep."},{"issue":"11","key":"491_CR15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/1744666X.2013.848792","volume":"9","author":"FV Castelino","year":"2013","unstructured":"Castelino FV, Varga J. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev Clin Immunol. 2013;9(11):1077\u201390.","journal-title":"Expert Rev Clin Immunol."},{"issue":"3","key":"491_CR16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2015.04.005","volume":"41","author":"L Cappelli","year":"2015","unstructured":"Cappelli L, Wigley FM. Management of Raynaud Phenomenon and digital ulcers in scleroderma. Rheum Dis Clin North Am. 2015;41(3):419\u201338.","journal-title":"Rheum Dis Clin North Am."},{"issue":"3","key":"491_CR17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2014.195","volume":"11","author":"NA Flavahan","year":"2015","unstructured":"Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol. 2015;11(3):146\u201358.","journal-title":"Nat Rev Rheumatol."},{"issue":"4","key":"491_CR18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2165\/00003495-200767040-00003","volume":"67","author":"JE Pope","year":"2007","unstructured":"Pope JE. The diagnosis and treatment of Raynaud\u2019s phenomenon: a practical approach. Drugs. 2007;67(4):517\u201325.","journal-title":"Drugs."},{"issue":"2","key":"491_CR19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","volume":"44","author":"AE Thompson","year":"2005","unstructured":"Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud\u2019s phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44(2):145\u201350.","journal-title":"Rheumatology (Oxford)."},{"issue":"8","key":"491_CR20","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"AE Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44(8):1841\u20137.","journal-title":"Arthritis Rheum."},{"key":"491_CR21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/IBPC.S34803","volume":"6","author":"PA Meredith","year":"2013","unstructured":"Meredith PA, Elliott HL. A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS). Integr Blood Press Control. 2013;6:79\u201387.","journal-title":"Integr Blood Press Control."},{"issue":"3","key":"491_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/14740338.2014.872238","volume":"13","author":"G Murdaca","year":"2014","unstructured":"Murdaca G, Spano F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf. 2014;13(3):295\u2013305.","journal-title":"Expert Opin Drug Saf."},{"issue":"9","key":"491_CR23","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","volume":"65","author":"T Tingey","year":"2013","unstructured":"Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013;65(9):1460\u201371.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"12","key":"491_CR24","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"JH Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985\u201393.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"491_CR25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"491_CR26","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1753193413516242","volume":"39","author":"L Uppal","year":"2014","unstructured":"Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud\u2019s syndrome associated with scleroderma. J Hand Surg Eur Vol. 2014;39(8):876\u201380.","journal-title":"J Hand Surg Eur Vol."},{"issue":"9","key":"491_CR27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","volume":"40","author":"C Muangchan","year":"2013","unstructured":"Muangchan C, Baron M, Pope J. The 15\u00a0% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol. 2013;40(9):1545\u201356.","journal-title":"J Rheumatol."},{"issue":"4","key":"491_CR28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340.","journal-title":"N Engl J Med."},{"issue":"5","key":"491_CR29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","volume":"45","author":"LJ Rubin","year":"2015","unstructured":"Rubin LJ, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45(5):1303\u201313.","journal-title":"Eur Respir J."},{"issue":"1","key":"491_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","volume":"129","author":"KM Olsson","year":"2014","unstructured":"Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57\u201365.","journal-title":"Circulation."},{"issue":"6","key":"491_CR31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.semarthrit.2014.12.001","volume":"44","author":"N Bose","year":"2015","unstructured":"Bose N, Chiesa-Vottero A, Chatterjee S. Scleroderma renal crisis. Semin Arthritis Rheum. 2015;44(6):687\u201394.","journal-title":"Semin Arthritis Rheum."},{"issue":"Suppl 2","key":"491_CR32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/annrheumdis-2015-eular.4695","volume":"74","author":"O Kowal-Bielecka","year":"2015","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis [abstract]. Ann Rheum Dis. 2015;74(Suppl 2):90\u20131. doi: 10.1136\/annrheumdis-2015-eular.4695 .","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"491_CR33","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351\u20138.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"491_CR34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH Hoogen van den","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24\u00a0week randomized double-blind trial, followed by a 24\u00a0week observational trial. Br J Rheumatol. 1996;35(4):364\u201372.","journal-title":"Br J Rheumatol."},{"issue":"2","key":"491_CR35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","volume":"36","author":"SR Johnson","year":"2009","unstructured":"Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009;36(2):323\u20139.","journal-title":"J Rheumatol."},{"issue":"8","key":"491_CR36","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00296-011-1967-y","volume":"32","author":"H Poormoghim","year":"2012","unstructured":"Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int. 2012;32(8):2431\u201344.","journal-title":"Rheumatol Int."},{"issue":"25","key":"491_CR37","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366.","journal-title":"N Engl J Med."},{"issue":"1","key":"491_CR38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.leu.2403996","volume":"20","author":"M Okamoto","year":"2006","unstructured":"Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20(1):172\u20133.","journal-title":"Leukemia."},{"issue":"4","key":"491_CR39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","volume":"44","author":"SL Bosello","year":"2015","unstructured":"Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428\u201336.","journal-title":"Semin Arthritis Rheum."},{"key":"491_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49:271\u201380.","journal-title":"Rheumatology (Oxford)."},{"key":"491_CR41","author":"D Giuggioli","year":"2015","unstructured":"Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015. doi: 10.1016\/j.autrev.2015.07.008 .","journal-title":"Autoimmun Rev."},{"issue":"11","key":"491_CR42","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","volume":"63","author":"J Pope","year":"2011","unstructured":"Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63(11):3547\u201351.","journal-title":"Arthritis Rheum."},{"key":"491_CR43","author":"JM Laar van","year":"2015","unstructured":"van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology (Oxford). 2015. doi: 10.1093\/rheumatology\/kev117 .","journal-title":"Rheumatology (Oxford)."},{"issue":"24","key":"491_CR44","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Laar van","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490\u20138. doi: 10.1001\/jama.2014.6368 .","journal-title":"JAMA."},{"issue":"8","key":"491_CR45","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","volume":"66","author":"EL Herzog","year":"2014","unstructured":"Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014;66(8):1967\u201378.","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"491_CR46","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962\u201370.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"491_CR47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.semarthrit.2014.09.003","volume":"44","author":"M Iudici","year":"2015","unstructured":"Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, et al. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. Sem Arthritis Rheum. 2015;44(4):437\u201344.","journal-title":"Sem Arthritis Rheum."},{"issue":"8","key":"491_CR48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/apt.12479","volume":"38","author":"SC Shah","year":"2013","unstructured":"Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925\u201334.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"491_CR49","first-page":"112","volume":"3","author":"AC Dukowicz","year":"2007","unstructured":"Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3(2):112\u201322.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"491_CR50","unstructured":"Dima A, Balanescu P, Baicus C. Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases. Rom J Intern Med. 2014;52(2):55\u201367."},{"issue":"7","key":"491_CR51","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72(7):1217\u201320.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"491_CR52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/vhrm.2006.2.3.303","volume":"2","author":"R Weiss","year":"2006","unstructured":"Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2006;2(3):303\u20138.","journal-title":"Vasc Health Risk Manag."},{"issue":"2","key":"491_CR53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","volume":"10","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127\u201340.","journal-title":"Nat Rev Drug Discov."},{"key":"491_CR54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.bi.64.070195.003201","volume":"64","author":"C Schindler","year":"1995","unstructured":"Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621\u201351.","journal-title":"Annu Rev Biochem."},{"issue":"4","key":"491_CR55","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/jid.2013.476","volume":"134","author":"N Okiyama","year":"2014","unstructured":"Okiyama N, Furumoto Y, Villarroel VA, Linton JT, Tsai WL, Gutermuth J, et al. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol. 2014;134(4):992\u20131000.","journal-title":"J Invest Dermatol."},{"issue":"10","key":"491_CR56","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/art.27647","volume":"62","author":"C Beyer","year":"2010","unstructured":"Beyer C, Schett G, Distler O, Distler JH. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum. 2010;62(10):2831\u201344.","journal-title":"Arthritis Rheum."},{"key":"491_CR57","doi-asserted-by":"crossref","unstructured":"Kwakkenbos L, Jewett LR, Baron M, Bartlett SJ, Furst D, Gottesman K, et al. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ open. 2013;3(8).","DOI":"10.1136\/bmjopen-2013-003563"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0491-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0491-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0491-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T11:58:58Z","timestamp":1567425538000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0491-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0491-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]}}}